<?xml version="1.0" encoding="UTF-8"?><measure><measureDetails><uuid>40280381-52fc-3a32-0153-1a2951250b12</uuid><title>Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients</title><shortTitle>CMS141</shortTitle><emeasureid>141</emeasureid><guid>8479f6d6-4200-4fd0-9438-30048ebe3e29</guid><version>6.1.000</version><nqfid extension="0385" root="2.16.840.1.113883.3.560.1"/><period calenderYear="true" uuid="40280381-3d61-56a7-013e-6b81e70055b1"><startDate>00000101</startDate><stopDate>00001231</stopDate></period><steward id="83e9797c-adec-4446-8c35-3ffd5d981c66">PCPI(R) Foundation (PCPI[R])</steward><developers><developer id="d041e15c-a7a0-41b8-be5b-87340ecd14bc">American Medical Association (AMA)</developer><developer id="83e9797c-adec-4446-8c35-3ffd5d981c66">PCPI(R) Foundation (PCPI[R])</developer></developers><endorsement id="2.16.840.1.113883.3.560">National Quality Forum</endorsement><description>Percentage of patients aged 18 through 80 years with AJCC Stage III colon cancer who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or have previously received adjuvant chemotherapy within the 12-month reporting period</description><copyright>Copyright 2015 American Society of Clinical Oncology, National Comprehensive Cancer Network Association and American Medical Association. All Rights Reserved.</copyright><disclaimer>The Measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications. &#xD;
&#xD;
The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, eg, use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. &#xD;
&#xD;
Commercial uses of the Measures require a license agreement between the user and the PCPI(R) Foundation (PCPI[R]), the American Medical Association (AMA), National Comprehensive Cancer Network (NCCN) or American Society of Clinical Oncology (ASCO).  Neither the AMA, nor NCCN, nor ASCO, nor the AMA-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI), now known as the PCPI, nor their members shall be responsible for any use of the Measures.&#xD;
&#xD;
AMA and PCPI encourage use of the Measures by other health care professionals, where appropriate.&#xD;
&#xD;
THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.&#xD;
&#xD;
Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, NCCN, ASCO, the PCPI and its members and former members of the AMA-PCPI disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT[R]) or other coding contained in the specifications. &#xD;
&#xD;
CPT(R) contained in the Measure specifications is copyright 2004-2015 American Medical Association. LOINC(R) is copyright 2004-2015 Regenstrief Institute, Inc. This material contains SNOMED CLINICAL TERMS (SNOMED CT[R]) copyright 2004-2015 International Health Terminology Standards Development Organisation (IHTSDO). ICD-10 is copyright 2015 World Health Organization. All Rights Reserved.&#xD;
&#xD;
Due to technical limitations, registered trademarks are indicated by (R) or [R].</disclaimer><scoring id="PROPOR">Proportion</scoring><types><type id="PROCESS">Process</type></types><componentMeasures/><itemCount/><stratification>None</stratification><riskAdjustment>None</riskAdjustment><aggregation>None</aggregation><rationale>The receipt of adjuvant chemotherapy in AJCC Stage III colon cancer patients following primary surgical treatment is associated with a significant survival benefit.</rationale><recommendations>For patients with stage III disease, the panel recommends 6 months of adjuvant chemotherapy after primary surgical treatment. The treatment options are: FOLFOX or CapeOx (both category 1 and preferred); FLOX (category 1); or single-agent capecitabine or 5-FU/LV in patients for whom oxaliplatin therapy is believed to be inappropriate. (NCCN, 2015) &#xD;
&#xD;
A shortage of LV recently existed in the United States. No specific data are available to guide management under these circumstances, and all proposed strategies are empiric. The panel recommends several possible options to help alleviate the problems associated with this shortage. One is the use of levoleucovorin, which is commonly used in Europe. A dose of 200 mg/m2 of leucovorin is equivalent to 400 mg/m2 of standard LV. Another option is for practices or institutions to use lower doses of LV for all doses in all patients, because the panel feels that lower doses are likely to be as efficacious as higher doses, based on several studies. Finally, if none of the above options is available, treatment without LV would be reasonable. For patients who tolerate this without grade II or higher toxicity, a modest increase in 5-FU dose (in the range of 10%) may be considered. (NCCN, 2015)</recommendations><improvementNotations>Higher score indicates better quality</improvementNotations><references><reference>National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Colon Cancer. Version 3.2015. Available at: http://www.nccn.org.</reference></references><definitions>Adjuvant Chemotherapy - According to current NCCN guidelines, the following therapies are recommended: 5-FU/LV/oxaliplatin (FOLFOX) or capecitabine/oxaliplatin (CapeOx) (both category 1 and preferred); bolus 5-FU/LV/oxaliplatin (FLOX) (category 1); or single-agent capecitabine or 5-FU/LV in patients felt to be inappropriate for oxaliplatin therapy (NCCN). See clinical recommendation statement for cases where leucovorin is not available.       &#xD;
&#xD;
Prescribed - May include prescription ordered for the patient for adjuvant chemotherapy at one or more visits in the 12-month period OR patient already receiving adjuvant chemotherapy as documented in the current medication list.</definitions><guidance>The measure logic option that includes the combination of 5-FU/LV/oxaliplatin will capture either FOLFOX or FLOX.  &#xD;
&#xD;
For the eCQM version of this measure, the denominator for this measure has been limited to patients with a first ever lifetime diagnosis of colon cancer recorded during the 12 month reporting period. The numerator captures patients who are prescribed adjuvant chemotherapy or received adjuvant chemotherapy during the 12 month period. "Referred for Chemotherapy" is not separately specified, as this option can be captured either through the "Medication Order: Chemotherapy for Colon Cancer" numerator option or the patient reason exception: "Medication, Administered not done: Patient Reason" for "Chemotherapy for Colon Cancer". Additional valid medical reason exceptions might include acute renal insufficiency, neutropenia, or leukopenia. Date of colon cancer diagnosis is defined as date of first pathologic diagnosis.&#xD;
&#xD;
The requirement of "Count &gt;=2 of Encounter, Performed" is to establish that the eligible professional has an existing relationship with the patient.&#xD;
&#xD;
The denominator exception "Clinical Trial Participant" data element should be specific to colon cancer. For instance, the patient should be participating in a clinical trial related to colon cancer treatment in order to meet the "Clinical Trial Participant" data element in the denominator exceptions. In the given example, the reason the patient was not referred, prescribed, or previously administered adjuvant chemotherapy is because he or she is in a clinical trial and may be receiving different treatments.</guidance><transmissionFormat>TBD</transmissionFormat><initialPopDescription>All patients aged 18 through 80 years with colon cancer</initialPopDescription><denominatorDescription>Equals Initial Population with AJCC Stage III colon cancer</denominatorDescription><denominatorExclusionsDescription>None</denominatorExclusionsDescription><numeratorDescription>Patients who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or who have previously received adjuvant chemotherapy within the 12 month reporting period</numeratorDescription><numeratorExclusionsDescription>Not Applicable</numeratorExclusionsDescription><denominatorExceptionsDescription>Documentation of medical reason(s) for not referring for or prescribing adjuvant chemotherapy (eg, medical co-morbidities, diagnosis date more than 5 years prior to the current visit date, patient's diagnosis date is within 120 days of the end of the 12 month reporting period, patient's cancer has metastasized, medical contraindication/allergy, poor performance status, other medical reasons)&#xD;
Documentation of patient reason(s) for not referring for or prescribing adjuvant chemotherapy (eg, patient refusal, other patient reasons)&#xD;
Documentation of system reason(s) for not referring for or prescribing adjuvant chemotherapy (eg, patient is currently enrolled in a clinical trial that precludes prescription of chemotherapy, other system reasons)</denominatorExceptionsDescription><supplementalData>For every patient evaluated by this measure also identify payer, race, ethnicity and sex</supplementalData><qualityMeasureSet uuid="e3e49d76-f87e-4f14-9c33-1a3bf7449d63">None</qualityMeasureSet>
<finalizedDate value="201603071124-0600"/>
</measureDetails><supplementalDataElements><elementRef id="40280381-3d61-56a7-013e-6b81e70055ac" name="ONC Administrative Sex"/><elementRef id="40280381-3d61-56a7-013e-6b81e70055ad" name="Race"/><elementRef id="40280381-3d61-56a7-013e-6b81e70055ae" name="Ethnicity"/><elementRef id="40280381-3d61-56a7-013e-6b81e70055af" name="Payer"/></supplementalDataElements><riskAdjustmentVariables/><subTreeLookUp><subTree displayName="Occurrence A of $OVorF2FEncounter" instance="A" instanceOf="DF574973-CCD0-4C79-BFE5-87505B22DA44" qdmVariable="true" uuid="0A850DCC-6A45-4A25-874C-909E8732E67E"><relationalOp displayName="During" type="DURING"><setOp displayName="Union" type="union"><elementRef displayName="Office Visit : Encounter, Performed" id="40280381-3d61-56a7-013e-6b81e70055b3" type="qdm"/><elementRef displayName="Face-to-Face Interaction : Encounter, Performed" id="b78c6b3d-278b-4402-a806-05f5f15bca1e" type="qdm"/></setOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-6b81e70055b1" type="qdm"/></relationalOp></subTree><subTree displayName="Age greater than or equal 18" qdmVariable="false" uuid="333CD3AA-D85E-4D99-B4C5-CD6B1E957139"><functionalOp displayName="Age&gt;= 18 years at" operatorType="Greater Than or Equal To" quantity="18" type="AGE AT" unit="years"><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-6b81e70055b1" type="qdm"/></functionalOp></subTree><subTree displayName="Age less than 80" qdmVariable="false" uuid="839A4AB2-7953-4F50-9638-F70DFB6506FE"><functionalOp displayName="Age&lt; 80 years at" operatorType="Less Than" quantity="80" type="AGE AT" unit="years"><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-6b81e70055b1" type="qdm"/></functionalOp></subTree><subTree displayName="Capecitabine Not Done" qdmVariable="false" uuid="7411E8D4-B0FC-4A30-8E04-AE234DBD519E"><relationalOp displayName="Starts During" type="SDU"><setOp displayName="Union" type="union"><elementRef displayName="Chemotherapy for Colon Cancer - Capecitabine : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155cd" type="qdm"><attribute attrUUID="d4b16234-aa36-4dc8-be8b-218d9903a235" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d7"/></elementRef><elementRef displayName="Chemotherapy for Colon Cancer - Capecitabine : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155cd" type="qdm"><attribute attrUUID="39d40c67-76ac-4924-a74a-98d1d104e84f" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d8"/></elementRef><elementRef displayName="Chemotherapy for Colon Cancer - Capecitabine : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155cd" type="qdm"><attribute attrUUID="c9441d5a-6fe8-45cf-b9f1-2e7495bebae7" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d9"/></elementRef><elementRef displayName="Chemotherapy for Colon Cancer - Capecitabine Ingredient : Medication, Order" id="445bfd91-8bbd-44be-aea2-63e1a9178140" type="qdm"><attribute attrUUID="f7262d8c-fbd3-499c-965f-ceecddea9816" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d7"/></elementRef><elementRef displayName="Chemotherapy for Colon Cancer - Capecitabine Ingredient : Medication, Order" id="445bfd91-8bbd-44be-aea2-63e1a9178140" type="qdm"><attribute attrUUID="351a17ab-461d-47ca-a959-acbb354b56c8" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d8"/></elementRef><elementRef displayName="Chemotherapy for Colon Cancer - Capecitabine Ingredient : Medication, Order" id="445bfd91-8bbd-44be-aea2-63e1a9178140" type="qdm"><attribute attrUUID="021735f0-b2d5-45ea-951b-343c78674ef0" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d9"/></elementRef></setOp><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="0A850DCC-6A45-4A25-874C-909E8732E67E" type="subTree"/></relationalOp></subTree><subTree displayName="Count 2 Encounters during MP" qdmVariable="false" uuid="6EF78216-C353-4C0B-88B2-C1F05D0373B6"><functionalOp displayName="Count&gt;= 2 " operatorType="Greater Than or Equal To" quantity="2" type="COUNT"><relationalOp displayName="During" type="DURING"><setOp displayName="Union" type="union"><elementRef displayName="Office Visit : Encounter, Performed" id="40280381-3d61-56a7-013e-6b81e70055b3" type="qdm"/><elementRef displayName="Patient Provider Interaction : Encounter, Performed" id="40280381-3d61-56a7-013e-6b81e70055b5" type="qdm"/></setOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-6b81e70055b1" type="qdm"/></relationalOp></functionalOp></subTree><subTree displayName="Dx Colon Cancer 120 days SBE MP" qdmVariable="false" uuid="F09ABF11-F56E-42CF-AA95-B1982F78A354"><relationalOp displayName="&lt;= 120 days Starts Before End Of" operatorType="Less Than or Equal To" quantity="120" type="SBE" unit="days"><subTreeRef displayName="FirstDxColonCancerMP" id="D2E65C0C-6082-4315-BF0F-FC46EC23D84B" type="subTree"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-6b81e70055b1" type="qdm"/></relationalOp></subTree><subTree displayName="Dx Colon Cancer overlaps OccA Encounter" qdmVariable="false" uuid="46697385-43AB-437E-A769-85AC19D279D6"><relationalOp displayName="Overlaps" type="Overlap"><subTreeRef displayName="FirstDxColonCancerMP" id="D2E65C0C-6082-4315-BF0F-FC46EC23D84B" type="subTree"/><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="0A850DCC-6A45-4A25-874C-909E8732E67E" type="subTree"/></relationalOp></subTree><subTree displayName="Exceptions overlap OccA Encounter" qdmVariable="false" uuid="BD145842-A4D4-4550-9C81-4C1432B55CDA"><relationalOp displayName="Overlaps" type="Overlap"><setOp displayName="Union" type="union"><elementRef displayName="Metastatic Sites Common to Colon Cancer : Diagnosis" id="31e6edfb-5cc1-40d4-9e3a-993dbaf7c4c0" type="qdm"/><elementRef displayName="Allergy to Antineoplastic Therapy : Diagnosis" id="bb8ef530-7761-41b6-bb12-82b04eab31d6" type="qdm"/><elementRef displayName="Intolerance to Antineoplastic Therapy : Diagnosis" id="08716b20-43cb-4799-9b0d-2b96d7214788" type="qdm"/><elementRef displayName="ECOG Performance Status-Poor : Patient Characteristic" id="7af2ae9d-285a-4c7e-b426-3d51449ad01d" type="qdm"/><elementRef displayName="Clinical Trial Participant : Patient Characteristic Clinical Trial Participant" id="630a05f2-030f-4801-9099-2284f53b62a7" type="qdm"/><elementRef displayName="Chemotherapy for Colon Cancer - Capecitabine : Medication, Intolerance" id="fa81a7d9-f803-4b67-b5a1-3c86d7de69ba" type="qdm"/><elementRef displayName="Chemotherapy for Colon Cancer - Capecitabine Ingredient : Medication, Allergy" id="73059436-4618-4ca7-a737-d22bc64e7d3a" type="qdm"/><elementRef displayName="Chemotherapy for Colon Cancer - Fluorouracil : Medication, Intolerance" id="e4de8293-9d02-4e36-90aa-e250b96297a4" type="qdm"/><elementRef displayName="Chemotherapy for Colon Cancer - Fluorouracil Ingredient : Medication, Allergy" id="ef02cc4e-5a2b-472c-b903-854dd2e3b4c0" type="qdm"/><elementRef displayName="Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin : Medication, Intolerance" id="e450138c-a166-472a-a6be-2d3f98219013" type="qdm"/><elementRef displayName="Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin Ingredient : Medication, Allergy" id="e17a0208-542a-43e6-80e1-c305a64e49b2" type="qdm"/><elementRef displayName="Chemotherapy for Colon Cancer - Oxaliplatin : Medication, Intolerance" id="5761ddd1-fde5-4f7f-8945-d26146d71ada" type="qdm"/><elementRef displayName="Chemotherapy for Colon Cancer - Oxaliplatin Ingredient : Medication, Allergy" id="c044f418-6947-4a43-9f94-e89964f8ffaf" type="qdm"/></setOp><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="0A850DCC-6A45-4A25-874C-909E8732E67E" type="subTree"/></relationalOp></subTree><subTree displayName="FirstDxColonCancerMP" qdmVariable="true" uuid="D2E65C0C-6082-4315-BF0F-FC46EC23D84B"><functionalOp displayName="Satisfies All" type="SATISFIES ALL"><elementRef displayName="Colon Cancer : Diagnosis" id="9c066eb2-5266-42aa-9371-3b77e7bd4c36" type="qdm"/><functionalOp displayName="First" type="FIRST"><elementRef displayName="Colon Cancer : Diagnosis" id="9c066eb2-5266-42aa-9371-3b77e7bd4c36" type="qdm"/></functionalOp><relationalOp displayName="Starts During" type="SDU"><elementRef displayName="Colon Cancer : Diagnosis" id="9c066eb2-5266-42aa-9371-3b77e7bd4c36" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-6b81e70055b1" type="qdm"/></relationalOp></functionalOp></subTree><subTree displayName="Fluorouracil Not Done" qdmVariable="false" uuid="00F23AFC-3499-4735-A2B0-EDA4AA9B922F"><relationalOp displayName="Starts During" type="SDU"><setOp displayName="Union" type="union"><elementRef displayName="Chemotherapy for Colon Cancer - Fluorouracil : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155c6" type="qdm"><attribute attrUUID="6d0c3f51-ba0e-4d67-a723-0c366c5e17ca" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d7"/></elementRef><elementRef displayName="Chemotherapy for Colon Cancer - Fluorouracil : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155c6" type="qdm"><attribute attrUUID="665bb92d-2421-4ddf-ad44-a81881084b31" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d8"/></elementRef><elementRef displayName="Chemotherapy for Colon Cancer - Fluorouracil : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155c6" type="qdm"><attribute attrUUID="ce26609e-52d2-4266-ba93-c8ab1850eef7" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d9"/></elementRef><elementRef displayName="Chemotherapy for Colon Cancer - Fluorouracil Ingredient : Medication, Order" id="14129bce-013d-45e9-9490-b7e0e29585c5" type="qdm"><attribute attrUUID="f1895ff0-26fe-4a21-83ea-7cc9c42e35df" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d7"/></elementRef><elementRef displayName="Chemotherapy for Colon Cancer - Fluorouracil Ingredient : Medication, Order" id="14129bce-013d-45e9-9490-b7e0e29585c5" type="qdm"><attribute attrUUID="fe7e5ecb-3710-4196-a0b0-e7b64d75142d" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d8"/></elementRef><elementRef displayName="Chemotherapy for Colon Cancer - Fluorouracil Ingredient : Medication, Order" id="14129bce-013d-45e9-9490-b7e0e29585c5" type="qdm"><attribute attrUUID="935ffb59-110e-49bb-8859-af94f64d24bf" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d9"/></elementRef></setOp><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="0A850DCC-6A45-4A25-874C-909E8732E67E" type="subTree"/></relationalOp></subTree><subTree displayName="Leucovorin and Levo Leucovorin Not Done" qdmVariable="false" uuid="EDF1199F-F0E7-41C4-9FDE-1476AB1D563D"><relationalOp displayName="Starts During" type="SDU"><setOp displayName="Union" type="union"><elementRef displayName="Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155c9" type="qdm"><attribute attrUUID="392412dc-fe2d-4c15-8443-0976ae3c7a45" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d7"/></elementRef><elementRef displayName="Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155c9" type="qdm"><attribute attrUUID="093e45ac-dacb-4012-a3a7-0984d3e6c54d" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d8"/></elementRef><elementRef displayName="Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155c9" type="qdm"><attribute attrUUID="7404cb9a-cf53-4109-82d5-803b08c7dd47" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d9"/></elementRef><elementRef displayName="Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin Ingredient : Medication, Order" id="e05c8bb8-00e6-4293-a6dc-6ca243cc0412" type="qdm"><attribute attrUUID="861809e2-3521-498e-ae21-387cb4e5aeec" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d7"/></elementRef><elementRef displayName="Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin Ingredient : Medication, Order" id="e05c8bb8-00e6-4293-a6dc-6ca243cc0412" type="qdm"><attribute attrUUID="d6ff2b47-f66b-4339-bbea-b98e21ef00ba" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d8"/></elementRef><elementRef displayName="Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin Ingredient : Medication, Order" id="e05c8bb8-00e6-4293-a6dc-6ca243cc0412" type="qdm"><attribute attrUUID="7c4cd95e-a756-4ea8-8a67-727f1a022419" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d9"/></elementRef></setOp><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="0A850DCC-6A45-4A25-874C-909E8732E67E" type="subTree"/></relationalOp></subTree><subTree displayName="Medication Administered Capecitabine" qdmVariable="false" uuid="D6DC143B-7F86-4689-8AB7-F7397E9F7ED6"><functionalOp displayName="Satisfies All" type="SATISFIES ALL"><elementRef displayName="Chemotherapy for Colon Cancer - Capecitabine : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155cd" type="qdm"/><relationalOp displayName="Starts After Start Of" type="SAS"><elementRef displayName="Chemotherapy for Colon Cancer - Capecitabine : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155cd" type="qdm"/><elementRef displayName="Occurrence A of Pathology Evaluation : Procedure, Performed" id="94aaed17-c39e-49b7-bd0a-0c9865c587f1" type="qdm"><attribute attrUUID="1e981246-d59f-49b5-94ea-03e7a5e29c76" mode="Check if Present" name="result"/></elementRef></relationalOp><relationalOp displayName="Starts Before End Of" type="SBE"><elementRef displayName="Chemotherapy for Colon Cancer - Capecitabine : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155cd" type="qdm"/><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="0A850DCC-6A45-4A25-874C-909E8732E67E" type="subTree"/></relationalOp></functionalOp></subTree><subTree displayName="Medication Administered Fluorouracil" qdmVariable="false" uuid="BD4E0BDD-D126-4C87-8E2B-0BADA34B412D"><functionalOp displayName="Satisfies All" type="SATISFIES ALL"><elementRef displayName="Chemotherapy for Colon Cancer - Fluorouracil : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155c6" type="qdm"/><relationalOp displayName="Starts After Start Of" type="SAS"><elementRef displayName="Chemotherapy for Colon Cancer - Fluorouracil : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155c6" type="qdm"/><elementRef displayName="Occurrence A of Pathology Evaluation : Procedure, Performed" id="94aaed17-c39e-49b7-bd0a-0c9865c587f1" type="qdm"><attribute attrUUID="8494b458-0d97-492a-9a1b-fd00910ebda8" mode="Check if Present" name="result"/></elementRef></relationalOp><relationalOp displayName="Starts Before End Of" type="SBE"><elementRef displayName="Chemotherapy for Colon Cancer - Fluorouracil : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155c6" type="qdm"/><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="0A850DCC-6A45-4A25-874C-909E8732E67E" type="subTree"/></relationalOp></functionalOp></subTree><subTree displayName="Medication Administered Leucovorin and LevoLeucovorin" qdmVariable="false" uuid="22D3B9A8-B25B-45F0-87F3-27152440D402"><functionalOp displayName="Satisfies All" type="SATISFIES ALL"><elementRef displayName="Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155c9" type="qdm"/><relationalOp displayName="Starts After Start Of" type="SAS"><elementRef displayName="Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155c9" type="qdm"/><elementRef displayName="Occurrence A of Pathology Evaluation : Procedure, Performed" id="94aaed17-c39e-49b7-bd0a-0c9865c587f1" type="qdm"><attribute attrUUID="9e15418e-cb0e-4bf6-8da8-688e83c1b6bc" mode="Check if Present" name="result"/></elementRef></relationalOp><relationalOp displayName="Starts Before End Of" type="SBE"><elementRef displayName="Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155c9" type="qdm"/><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="0A850DCC-6A45-4A25-874C-909E8732E67E" type="subTree"/></relationalOp></functionalOp></subTree><subTree displayName="Medication Administered Oxalipatin" qdmVariable="false" uuid="7876F589-8186-4A04-B942-A8A034662313"><functionalOp displayName="Satisfies All" type="SATISFIES ALL"><elementRef displayName="Chemotherapy for Colon Cancer - Oxaliplatin : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155cb" type="qdm"/><relationalOp displayName="Starts After Start Of" type="SAS"><elementRef displayName="Chemotherapy for Colon Cancer - Oxaliplatin : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155cb" type="qdm"/><elementRef displayName="Occurrence A of Pathology Evaluation : Procedure, Performed" id="94aaed17-c39e-49b7-bd0a-0c9865c587f1" type="qdm"><attribute attrUUID="23784935-052a-47c2-9599-940ebd23719c" mode="Check if Present" name="result"/></elementRef></relationalOp><relationalOp displayName="Starts Before End Of" type="SBE"><elementRef displayName="Chemotherapy for Colon Cancer - Oxaliplatin : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155cb" type="qdm"/><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="0A850DCC-6A45-4A25-874C-909E8732E67E" type="subTree"/></relationalOp></functionalOp></subTree><subTree displayName="Medication Order Capecitabine" qdmVariable="false" uuid="3FF6AE62-0E5C-4E53-ABED-C6F21C511858"><functionalOp displayName="Satisfies All" type="SATISFIES ALL"><elementRef displayName="Chemotherapy for Colon Cancer - Capecitabine : Medication, Order" id="b9fb378b-395c-4cae-8abd-058679817ba4" type="qdm"/><relationalOp displayName="Starts After Start Of" type="SAS"><elementRef displayName="Chemotherapy for Colon Cancer - Capecitabine : Medication, Order" id="b9fb378b-395c-4cae-8abd-058679817ba4" type="qdm"/><elementRef displayName="Occurrence A of Pathology Evaluation : Procedure, Performed" id="94aaed17-c39e-49b7-bd0a-0c9865c587f1" type="qdm"><attribute attrUUID="24a9c54c-4047-4fac-baab-6d28d1cc2e58" mode="Check if Present" name="result"/></elementRef></relationalOp><relationalOp displayName="Starts Before End Of" type="SBE"><elementRef displayName="Chemotherapy for Colon Cancer - Capecitabine : Medication, Order" id="b9fb378b-395c-4cae-8abd-058679817ba4" type="qdm"/><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="0A850DCC-6A45-4A25-874C-909E8732E67E" type="subTree"/></relationalOp></functionalOp></subTree><subTree displayName="Medication Order Fluorouracil" qdmVariable="false" uuid="22A047AE-B9AD-4CE0-80B7-79324ADA0AAF"><functionalOp displayName="Satisfies All" type="SATISFIES ALL"><elementRef displayName="Chemotherapy for Colon Cancer - Fluorouracil : Medication, Order" id="f0c2319a-9dea-4c7f-8802-2c458df6f4fd" type="qdm"/><relationalOp displayName="Starts After Start Of" type="SAS"><elementRef displayName="Chemotherapy for Colon Cancer - Fluorouracil : Medication, Order" id="f0c2319a-9dea-4c7f-8802-2c458df6f4fd" type="qdm"/><elementRef displayName="Occurrence A of Pathology Evaluation : Procedure, Performed" id="94aaed17-c39e-49b7-bd0a-0c9865c587f1" type="qdm"><attribute attrUUID="f858de76-f56f-43b2-a256-1f9fda96def8" mode="Check if Present" name="result"/></elementRef></relationalOp><relationalOp displayName="Starts Before End Of" type="SBE"><elementRef displayName="Chemotherapy for Colon Cancer - Fluorouracil : Medication, Order" id="f0c2319a-9dea-4c7f-8802-2c458df6f4fd" type="qdm"/><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="0A850DCC-6A45-4A25-874C-909E8732E67E" type="subTree"/></relationalOp></functionalOp></subTree><subTree displayName="Medication Order Leucovorin and LevoLeucovorin" qdmVariable="false" uuid="B603CE00-FF11-4058-8D11-A4D3B83AD2FC"><functionalOp displayName="Satisfies All" type="SATISFIES ALL"><elementRef displayName="Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin : Medication, Order" id="08cdff48-17ca-42d6-b2aa-0539f2952bca" type="qdm"/><relationalOp displayName="Starts After Start Of" type="SAS"><elementRef displayName="Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin : Medication, Order" id="08cdff48-17ca-42d6-b2aa-0539f2952bca" type="qdm"/><elementRef displayName="Occurrence A of Pathology Evaluation : Procedure, Performed" id="94aaed17-c39e-49b7-bd0a-0c9865c587f1" type="qdm"><attribute attrUUID="0299a4e4-240f-46f6-bc66-df20532999b8" mode="Check if Present" name="result"/></elementRef></relationalOp><relationalOp displayName="Starts Before End Of" type="SBE"><elementRef displayName="Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin : Medication, Order" id="08cdff48-17ca-42d6-b2aa-0539f2952bca" type="qdm"/><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="0A850DCC-6A45-4A25-874C-909E8732E67E" type="subTree"/></relationalOp></functionalOp></subTree><subTree displayName="Medication Order Oxalipatin" qdmVariable="false" uuid="FCD4ADE6-1E8A-42A8-BE4B-37E8AC1DE14A"><functionalOp displayName="Satisfies All" type="SATISFIES ALL"><elementRef displayName="Chemotherapy for Colon Cancer - Oxaliplatin : Medication, Order" id="4a322997-e3c9-46c4-9db1-8394f03d3a97" type="qdm"/><relationalOp displayName="Starts After Start Of" type="SAS"><elementRef displayName="Chemotherapy for Colon Cancer - Oxaliplatin : Medication, Order" id="4a322997-e3c9-46c4-9db1-8394f03d3a97" type="qdm"/><elementRef displayName="Occurrence A of Pathology Evaluation : Procedure, Performed" id="94aaed17-c39e-49b7-bd0a-0c9865c587f1" type="qdm"><attribute attrUUID="3a4892d0-67b2-401c-954b-eb686faf4ee9" mode="Check if Present" name="result"/></elementRef></relationalOp><relationalOp displayName="Starts Before End Of" type="SBE"><elementRef displayName="Chemotherapy for Colon Cancer - Oxaliplatin : Medication, Order" id="4a322997-e3c9-46c4-9db1-8394f03d3a97" type="qdm"/><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="0A850DCC-6A45-4A25-874C-909E8732E67E" type="subTree"/></relationalOp></functionalOp></subTree><subTree displayName="Occurrence A Clinical Staging Procedure" qdmVariable="false" uuid="D9A98FF5-EE7E-418E-BA44-635090B6A985"><setOp displayName="Intersection" type="intersection"><functionalOp displayName="Satisfies All" type="SATISFIES ALL"><elementRef displayName="Occurrence A of Pathology Evaluation : Procedure, Performed" id="94aaed17-c39e-49b7-bd0a-0c9865c587f1" type="qdm"/><relationalOp displayName="Starts Before End Of" type="SBE"><elementRef displayName="Occurrence A of Pathology Evaluation : Procedure, Performed" id="94aaed17-c39e-49b7-bd0a-0c9865c587f1" type="qdm"><attribute attrUUID="b46c0fd7-2570-4765-9b4a-6cf2462c8688" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6b81e70255e8"/></elementRef><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="0A850DCC-6A45-4A25-874C-909E8732E67E" type="subTree"/></relationalOp><relationalOp displayName="Starts After Or Concurrent With Start Of" type="SASORSCW"><elementRef displayName="Occurrence A of Pathology Evaluation : Procedure, Performed" id="94aaed17-c39e-49b7-bd0a-0c9865c587f1" type="qdm"><attribute attrUUID="ee2fe674-13b6-4c54-87a5-752696302c3a" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6b81e70255e8"/></elementRef><subTreeRef displayName="FirstDxColonCancerMP" id="D2E65C0C-6082-4315-BF0F-FC46EC23D84B" type="subTree"/></relationalOp></functionalOp><setOp displayName="Union" type="union"><setOp displayName="Intersection" type="intersection"><functionalOp displayName="Satisfies Any" type="SATISFIES ANY"><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="281ca9b3-d41e-4000-827b-ca94481461ad" type="qdm"/><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="281ca9b3-d41e-4000-827b-ca94481461ad" type="qdm"><attribute attrUUID="1e8bc851-a3fd-493f-b260-6b9212cde722" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6b81e70155b9"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="281ca9b3-d41e-4000-827b-ca94481461ad" type="qdm"><attribute attrUUID="86d011a2-3b05-472b-9a4a-012e10dad8f5" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6b81e70155ba"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="281ca9b3-d41e-4000-827b-ca94481461ad" type="qdm"><attribute attrUUID="c3d30df6-1e3f-474d-a13a-38b0702394db" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6b81e70155bb"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="281ca9b3-d41e-4000-827b-ca94481461ad" type="qdm"><attribute attrUUID="a7afdda0-6226-4202-b4e5-438b8338945d" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6b81e70155bc"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="281ca9b3-d41e-4000-827b-ca94481461ad" type="qdm"><attribute attrUUID="524654c3-ea20-4480-907a-458e1b7fcad5" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6b81e70155bd"/></elementRef></functionalOp><functionalOp displayName="Satisfies Any" type="SATISFIES ANY"><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="281ca9b3-d41e-4000-827b-ca94481461ad" type="qdm"/><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="281ca9b3-d41e-4000-827b-ca94481461ad" type="qdm"><attribute attrUUID="41a74989-c07e-4937-a9af-3bbd0e17456e" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6b81e70155be"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="281ca9b3-d41e-4000-827b-ca94481461ad" type="qdm"><attribute attrUUID="621b5f40-7246-4422-9c5f-fc825c7eda8d" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6b81e70155bf"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="281ca9b3-d41e-4000-827b-ca94481461ad" type="qdm"><attribute attrUUID="5b6a5584-8208-400a-a29b-b543c53dbed1" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6b81e70155c0"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="281ca9b3-d41e-4000-827b-ca94481461ad" type="qdm"><attribute attrUUID="1772a6f7-f0f0-46e8-aa01-697a1a379e0f" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6b81e70155c1"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="281ca9b3-d41e-4000-827b-ca94481461ad" type="qdm"><attribute attrUUID="58655dcf-a7c2-4a67-8fb7-cc9821126bd0" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6b81e70155c3"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="281ca9b3-d41e-4000-827b-ca94481461ad" type="qdm"><attribute attrUUID="a2dafad5-fd2a-4ad1-acad-5f35cb28dfcf" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6b81e70155c4"/></elementRef></functionalOp></setOp><functionalOp displayName="Satisfies All" type="SATISFIES ALL"><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="281ca9b3-d41e-4000-827b-ca94481461ad" type="qdm"/><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="281ca9b3-d41e-4000-827b-ca94481461ad" type="qdm"><attribute attrUUID="7d99b3fd-ab8a-4a04-ad6e-0b98684b851c" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6b81e70155bd"/></elementRef><elementRef displayName="Pathology Evaluation : Procedure, Performed" id="281ca9b3-d41e-4000-827b-ca94481461ad" type="qdm"><attribute attrUUID="511bd8a9-c540-4318-b606-cc1805ca3129" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6b81e70155c2"/></elementRef></functionalOp></setOp></setOp></subTree><subTree displayName="OVorF2FEncounter" qdmVariable="true" uuid="DF574973-CCD0-4C79-BFE5-87505B22DA44"><relationalOp displayName="During" type="DURING"><setOp displayName="Union" type="union"><elementRef displayName="Office Visit : Encounter, Performed" id="40280381-3d61-56a7-013e-6b81e70055b3" type="qdm"/><elementRef displayName="Face-to-Face Interaction : Encounter, Performed" id="b78c6b3d-278b-4402-a806-05f5f15bca1e" type="qdm"/></setOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-6b81e70055b1" type="qdm"/></relationalOp></subTree><subTree displayName="Oxaliplatin Not Done" qdmVariable="false" uuid="C7DE7DD6-27F2-4B8D-9A47-166E08B8F259"><relationalOp displayName="Starts During" type="SDU"><setOp displayName="Union" type="union"><elementRef displayName="Chemotherapy for Colon Cancer - Oxaliplatin : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155cb" type="qdm"><attribute attrUUID="cae59683-d08c-41e6-8190-6ab17f0fea81" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d7"/></elementRef><elementRef displayName="Chemotherapy for Colon Cancer - Oxaliplatin : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155cb" type="qdm"><attribute attrUUID="adad0f8e-afde-4e77-b99b-31d1693ab341" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d8"/></elementRef><elementRef displayName="Chemotherapy for Colon Cancer - Oxaliplatin : Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155cb" type="qdm"><attribute attrUUID="b684d876-f62c-450c-a218-00710b4d1331" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d9"/></elementRef><elementRef displayName="Chemotherapy for Colon Cancer - Oxaliplatin Ingredient : Medication, Order" id="5d2b04b5-57d4-49d9-b5d0-492ee17a8e8a" type="qdm"><attribute attrUUID="96083b49-1dec-4a69-9a50-928844ecab83" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d7"/></elementRef><elementRef displayName="Chemotherapy for Colon Cancer - Oxaliplatin Ingredient : Medication, Order" id="5d2b04b5-57d4-49d9-b5d0-492ee17a8e8a" type="qdm"><attribute attrUUID="b7550590-561d-44f3-93e0-3c6d8dd639a9" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d8"/></elementRef><elementRef displayName="Chemotherapy for Colon Cancer - Oxaliplatin Ingredient : Medication, Order" id="5d2b04b5-57d4-49d9-b5d0-492ee17a8e8a" type="qdm"><attribute attrUUID="c8bfe5ff-e91b-4e02-8041-4b43d71a32a7" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6b81e70255d9"/></elementRef></setOp><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="0A850DCC-6A45-4A25-874C-909E8732E67E" type="subTree"/></relationalOp></subTree></subTreeLookUp><measureGrouping><group sequence="1"><clause displayName="Initial Population 1" type="initialPopulation" uuid="BCFE8BFD-AF09-48C1-A546-C2DB33D0CB62"><logicalOp displayName="AND" type="and"><subTreeRef displayName="Age greater than or equal 18" id="333CD3AA-D85E-4D99-B4C5-CD6B1E957139" type="subTree"/><subTreeRef displayName="Age less than 80" id="839A4AB2-7953-4F50-9638-F70DFB6506FE" type="subTree"/><subTreeRef displayName="Count 2 Encounters during MP" id="6EF78216-C353-4C0B-88B2-C1F05D0373B6" type="subTree"/><subTreeRef displayName="Dx Colon Cancer overlaps OccA Encounter" id="46697385-43AB-437E-A769-85AC19D279D6" type="subTree"/></logicalOp></clause><clause displayName="Denominator 1" type="denominator" uuid="5D8535D1-74C3-4EF5-875C-90194A14ED01"><logicalOp displayName="AND" type="and"><subTreeRef displayName="Occurrence A Clinical Staging Procedure" id="D9A98FF5-EE7E-418E-BA44-635090B6A985" type="subTree"/></logicalOp></clause><clause displayName="Denominator Exceptions 1" type="denominatorExceptions" uuid="47E23C8B-6360-4763-A07F-28B19BCEBB27"><logicalOp displayName="OR" type="or"><subTreeRef displayName="Dx Colon Cancer 120 days SBE MP" id="F09ABF11-F56E-42CF-AA95-B1982F78A354" type="subTree"/><subTreeRef displayName="Exceptions overlap OccA Encounter" id="BD145842-A4D4-4550-9C81-4C1432B55CDA" type="subTree"/><logicalOp displayName="AND" type="and"><subTreeRef displayName="Capecitabine Not Done" id="7411E8D4-B0FC-4A30-8E04-AE234DBD519E" type="subTree"/><subTreeRef displayName="Fluorouracil Not Done" id="00F23AFC-3499-4735-A2B0-EDA4AA9B922F" type="subTree"/><subTreeRef displayName="Leucovorin and Levo Leucovorin Not Done" id="EDF1199F-F0E7-41C4-9FDE-1476AB1D563D" type="subTree"/><subTreeRef displayName="Oxaliplatin Not Done" id="C7DE7DD6-27F2-4B8D-9A47-166E08B8F259" type="subTree"/></logicalOp></logicalOp></clause><clause displayName="Numerator 1" type="numerator" uuid="AC6FC738-ADBB-4AB3-A195-63795C66F20D"><logicalOp displayName="AND" type="and"><logicalOp displayName="OR" type="or"><subTreeRef displayName="Medication Administered Capecitabine" id="D6DC143B-7F86-4689-8AB7-F7397E9F7ED6" type="subTree"/><subTreeRef displayName="Medication Order Capecitabine" id="3FF6AE62-0E5C-4E53-ABED-C6F21C511858" type="subTree"/><logicalOp displayName="AND" type="and"><subTreeRef displayName="Medication Administered Fluorouracil" id="BD4E0BDD-D126-4C87-8E2B-0BADA34B412D" type="subTree"/><subTreeRef displayName="Medication Administered Leucovorin and LevoLeucovorin" id="22D3B9A8-B25B-45F0-87F3-27152440D402" type="subTree"/></logicalOp><logicalOp displayName="AND" type="and"><subTreeRef displayName="Medication Order Fluorouracil" id="22A047AE-B9AD-4CE0-80B7-79324ADA0AAF" type="subTree"/><subTreeRef displayName="Medication Order Leucovorin and LevoLeucovorin" id="B603CE00-FF11-4058-8D11-A4D3B83AD2FC" type="subTree"/></logicalOp><logicalOp displayName="AND" type="and"><subTreeRef displayName="Medication Order Capecitabine" id="3FF6AE62-0E5C-4E53-ABED-C6F21C511858" type="subTree"/><subTreeRef displayName="Medication Order Oxalipatin" id="FCD4ADE6-1E8A-42A8-BE4B-37E8AC1DE14A" type="subTree"/></logicalOp><logicalOp displayName="AND" type="and"><subTreeRef displayName="Medication Administered Capecitabine" id="D6DC143B-7F86-4689-8AB7-F7397E9F7ED6" type="subTree"/><subTreeRef displayName="Medication Administered Oxalipatin" id="7876F589-8186-4A04-B942-A8A034662313" type="subTree"/></logicalOp><logicalOp displayName="AND" type="and"><subTreeRef displayName="Medication Administered Fluorouracil" id="BD4E0BDD-D126-4C87-8E2B-0BADA34B412D" type="subTree"/><subTreeRef displayName="Medication Administered Leucovorin and LevoLeucovorin" id="22D3B9A8-B25B-45F0-87F3-27152440D402" type="subTree"/><subTreeRef displayName="Medication Administered Oxalipatin" id="7876F589-8186-4A04-B942-A8A034662313" type="subTree"/></logicalOp><logicalOp displayName="AND" type="and"><subTreeRef displayName="Medication Order Fluorouracil" id="22A047AE-B9AD-4CE0-80B7-79324ADA0AAF" type="subTree"/><subTreeRef displayName="Medication Order Leucovorin and LevoLeucovorin" id="B603CE00-FF11-4058-8D11-A4D3B83AD2FC" type="subTree"/><subTreeRef displayName="Medication Order Oxalipatin" id="FCD4ADE6-1E8A-42A8-BE4B-37E8AC1DE14A" type="subTree"/></logicalOp></logicalOp></logicalOp></clause><clause displayName="denominatorExclusions" type="denominatorExclusions" uuid="0b27c29a-b0c3-46d2-a95f-f07a45b6cb28"><logicalOp displayName="AND" type="and"/></clause><clause displayName="numeratorExclusions" type="numeratorExclusions" uuid="009d482f-83a1-42a3-a5d6-925b79a39725"><logicalOp displayName="AND" type="and"/></clause><clause displayName="stratum" type="stratum" uuid="c7b8cf77-7db7-45ea-ad1d-790f9301dc6f"/></group></measureGrouping><elementLookUp><qdm datatype="Diagnosis" id="bb8ef530-7761-41b6-bb12-82b04eab31d6" name="Allergy to Antineoplastic Therapy" oid="2.16.840.1.113883.3.526.3.1280" suppDataElement="false" taxonomy="Grouping" uuid="bb8ef530-7761-41b6-bb12-82b04eab31d6" version="1.0"/><qdm datatype="Patient Characteristic Birthdate" id="b787e383-2a35-468d-bb36-c4a76d3b5e58" name="Birthdate" oid="21112-8" suppDataElement="false" taxonomy="SNOMED-CT" uuid="b787e383-2a35-468d-bb36-c4a76d3b5e58" version="1.0"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155cd" name="Chemotherapy for Colon Cancer - Capecitabine" oid="2.16.840.1.113883.3.526.3.1288" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6b81e70155cd" version="1"/><qdm datatype="Medication, Order" id="b9fb378b-395c-4cae-8abd-058679817ba4" name="Chemotherapy for Colon Cancer - Capecitabine" oid="2.16.840.1.113883.3.526.3.1288" suppDataElement="false" taxonomy="Grouping" uuid="b9fb378b-395c-4cae-8abd-058679817ba4" version="1.0"/><qdm datatype="Medication, Intolerance" id="fa81a7d9-f803-4b67-b5a1-3c86d7de69ba" name="Chemotherapy for Colon Cancer - Capecitabine" oid="2.16.840.1.113883.3.526.3.1288" suppDataElement="false" taxonomy="Grouping" uuid="fa81a7d9-f803-4b67-b5a1-3c86d7de69ba" version="1.0"/><qdm datatype="Medication, Allergy" id="73059436-4618-4ca7-a737-d22bc64e7d3a" name="Chemotherapy for Colon Cancer - Capecitabine Ingredient" oid="2.16.840.1.113883.3.526.3.1485" suppDataElement="false" taxonomy="Grouping" uuid="73059436-4618-4ca7-a737-d22bc64e7d3a" version="1.0"/><qdm datatype="Medication, Order" id="445bfd91-8bbd-44be-aea2-63e1a9178140" name="Chemotherapy for Colon Cancer - Capecitabine Ingredient" oid="2.16.840.1.113883.3.526.3.1485" suppDataElement="false" taxonomy="Grouping" uuid="445bfd91-8bbd-44be-aea2-63e1a9178140" version="1.0"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155c6" name="Chemotherapy for Colon Cancer - Fluorouracil" oid="2.16.840.1.113883.3.526.3.1289" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6b81e70155c6" version="1"/><qdm datatype="Medication, Order" id="f0c2319a-9dea-4c7f-8802-2c458df6f4fd" name="Chemotherapy for Colon Cancer - Fluorouracil" oid="2.16.840.1.113883.3.526.3.1289" suppDataElement="false" taxonomy="Grouping" uuid="f0c2319a-9dea-4c7f-8802-2c458df6f4fd" version="1.0"/><qdm datatype="Medication, Intolerance" id="e4de8293-9d02-4e36-90aa-e250b96297a4" name="Chemotherapy for Colon Cancer - Fluorouracil" oid="2.16.840.1.113883.3.526.3.1289" suppDataElement="false" taxonomy="Grouping" uuid="e4de8293-9d02-4e36-90aa-e250b96297a4" version="1.0"/><qdm datatype="Medication, Allergy" id="ef02cc4e-5a2b-472c-b903-854dd2e3b4c0" name="Chemotherapy for Colon Cancer - Fluorouracil Ingredient" oid="2.16.840.1.113883.3.526.3.1486" suppDataElement="false" taxonomy="Grouping" uuid="ef02cc4e-5a2b-472c-b903-854dd2e3b4c0" version="1.0"/><qdm datatype="Medication, Order" id="14129bce-013d-45e9-9490-b7e0e29585c5" name="Chemotherapy for Colon Cancer - Fluorouracil Ingredient" oid="2.16.840.1.113883.3.526.3.1486" suppDataElement="false" taxonomy="Grouping" uuid="14129bce-013d-45e9-9490-b7e0e29585c5" version="1.0"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155c9" name="Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin" oid="2.16.840.1.113883.3.526.3.1290" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6b81e70155c9" version="1"/><qdm datatype="Medication, Order" id="08cdff48-17ca-42d6-b2aa-0539f2952bca" name="Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin" oid="2.16.840.1.113883.3.526.3.1290" suppDataElement="false" taxonomy="Grouping" uuid="08cdff48-17ca-42d6-b2aa-0539f2952bca" version="1.0"/><qdm datatype="Medication, Intolerance" id="e450138c-a166-472a-a6be-2d3f98219013" name="Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin" oid="2.16.840.1.113883.3.526.3.1290" suppDataElement="false" taxonomy="Grouping" uuid="e450138c-a166-472a-a6be-2d3f98219013" version="1.0"/><qdm datatype="Medication, Allergy" id="e17a0208-542a-43e6-80e1-c305a64e49b2" name="Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin Ingredient" oid="2.16.840.1.113883.3.526.3.1490" suppDataElement="false" taxonomy="Grouping" uuid="e17a0208-542a-43e6-80e1-c305a64e49b2" version="1.0"/><qdm datatype="Medication, Order" id="e05c8bb8-00e6-4293-a6dc-6ca243cc0412" name="Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin Ingredient" oid="2.16.840.1.113883.3.526.3.1490" suppDataElement="false" taxonomy="Grouping" uuid="e05c8bb8-00e6-4293-a6dc-6ca243cc0412" version="1.0"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Medication, Administered" id="40280381-3d61-56a7-013e-6b81e70155cb" name="Chemotherapy for Colon Cancer - Oxaliplatin" oid="2.16.840.1.113883.3.526.3.1291" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6b81e70155cb" version="1"/><qdm datatype="Medication, Order" id="4a322997-e3c9-46c4-9db1-8394f03d3a97" name="Chemotherapy for Colon Cancer - Oxaliplatin" oid="2.16.840.1.113883.3.526.3.1291" suppDataElement="false" taxonomy="Grouping" uuid="4a322997-e3c9-46c4-9db1-8394f03d3a97" version="1.0"/><qdm datatype="Medication, Intolerance" id="5761ddd1-fde5-4f7f-8945-d26146d71ada" name="Chemotherapy for Colon Cancer - Oxaliplatin" oid="2.16.840.1.113883.3.526.3.1291" suppDataElement="false" taxonomy="Grouping" uuid="5761ddd1-fde5-4f7f-8945-d26146d71ada" version="1.0"/><qdm datatype="Medication, Allergy" id="c044f418-6947-4a43-9f94-e89964f8ffaf" name="Chemotherapy for Colon Cancer - Oxaliplatin Ingredient" oid="2.16.840.1.113883.3.526.3.1495" suppDataElement="false" taxonomy="Grouping" uuid="c044f418-6947-4a43-9f94-e89964f8ffaf" version="1.0"/><qdm datatype="Medication, Order" id="5d2b04b5-57d4-49d9-b5d0-492ee17a8e8a" name="Chemotherapy for Colon Cancer - Oxaliplatin Ingredient" oid="2.16.840.1.113883.3.526.3.1495" suppDataElement="false" taxonomy="Grouping" uuid="5d2b04b5-57d4-49d9-b5d0-492ee17a8e8a" version="1.0"/><qdm datatype="Procedure, Performed" id="94aaed17-c39e-49b7-bd0a-0c9865c587f1" instance="Occurrence A" name="Pathology Evaluation" oid="2.16.840.1.113883.3.526.3.1098" suppDataElement="false" taxonomy="Grouping" uuid="94aaed17-c39e-49b7-bd0a-0c9865c587f1" version="1.0"/><qdm datatype="Patient Characteristic Clinical Trial Participant" id="630a05f2-030f-4801-9099-2284f53b62a7" name="Clinical Trial Participant" oid="2.16.840.1.113883.3.526.3.1125" suppDataElement="false" taxonomy="Grouping" uuid="630a05f2-030f-4801-9099-2284f53b62a7" version="1.0"/><qdm datatype="Diagnosis" id="9c066eb2-5266-42aa-9371-3b77e7bd4c36" name="Colon Cancer" oid="2.16.840.1.113883.3.526.3.391" suppDataElement="false" taxonomy="Grouping" uuid="9c066eb2-5266-42aa-9371-3b77e7bd4c36" version="1.0"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6b81e70155b9" name="Colon Cancer Primary Tumor Size T1" oid="2.16.840.1.113883.3.526.3.1292" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6b81e70155b9" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6b81e70155ba" name="Colon Cancer Primary Tumor Size T2" oid="2.16.840.1.113883.3.526.3.1293" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6b81e70155ba" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6b81e70155bb" name="Colon Cancer Primary Tumor Size T3" oid="2.16.840.1.113883.3.526.3.1294" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6b81e70155bb" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6b81e70155bc" name="Colon Cancer Primary Tumor Size T4a" oid="2.16.840.1.113883.3.526.3.1295" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6b81e70155bc" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6b81e70155bd" name="Colon Cancer Primary Tumor Size T4b" oid="2.16.840.1.113883.3.526.3.1296" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6b81e70155bd" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6b81e70155be" name="Colon Cancer Regional Lymph Node Status N1" oid="2.16.840.1.113883.3.526.3.1297" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6b81e70155be" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6b81e70155bf" name="Colon Cancer Regional Lymph Node Status N1a" oid="2.16.840.1.113883.3.526.3.1327" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6b81e70155bf" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6b81e70155c0" name="Colon Cancer Regional Lymph Node Status N1b" oid="2.16.840.1.113883.3.526.3.1328" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6b81e70155c0" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6b81e70155c1" name="Colon Cancer Regional Lymph Node Status N1c" oid="2.16.840.1.113883.3.526.3.1298" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6b81e70155c1" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6b81e70155c2" name="Colon Cancer Regional Lymph Node Status N2" oid="2.16.840.1.113883.3.526.3.1299" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6b81e70155c2" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6b81e70155c3" name="Colon Cancer Regional Lymph Node Status N2a" oid="2.16.840.1.113883.3.526.3.1300" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6b81e70155c3" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6b81e70155c4" name="Colon Cancer Regional Lymph Node Status N2b" oid="2.16.840.1.113883.3.526.3.1301" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6b81e70155c4" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6b81e70255e8" name="Colon Distant Metastasis Status M0" oid="2.16.840.1.113883.3.526.3.1337" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6b81e70255e8" version="1"/><qdm datatype="Patient Characteristic" id="7af2ae9d-285a-4c7e-b426-3d51449ad01d" name="ECOG Performance Status-Poor" oid="2.16.840.1.113883.3.526.3.1279" suppDataElement="false" taxonomy="Grouping" uuid="7af2ae9d-285a-4c7e-b426-3d51449ad01d" version="1.0"/><qdm codeSystemName="CDC NCHS" datatype="Patient Characteristic Ethnicity" id="40280381-3d61-56a7-013e-6b81e70055ae" name="Ethnicity" oid="2.16.840.1.114222.4.11.837" suppDataElement="true" taxonomy="CDCREC" uuid="40280381-3d61-56a7-013e-6b81e70055ae" version="1"/><qdm datatype="Patient Characteristic Expired" id="0e274b54-f01d-4b83-8f64-55989b052aaf" name="Expired" oid="419099009" suppDataElement="false" taxonomy="SNOMED-CT" uuid="0e274b54-f01d-4b83-8f64-55989b052aaf" version="1.0"/><qdm datatype="Encounter, Performed" id="b78c6b3d-278b-4402-a806-05f5f15bca1e" name="Face-to-Face Interaction" oid="2.16.840.1.113883.3.464.1003.101.12.1048" suppDataElement="false" taxonomy="Grouping" uuid="b78c6b3d-278b-4402-a806-05f5f15bca1e" version="1.0"/><qdm datatype="Diagnosis" id="08716b20-43cb-4799-9b0d-2b96d7214788" name="Intolerance to Antineoplastic Therapy" oid="2.16.840.1.113883.3.526.3.1287" suppDataElement="false" taxonomy="Grouping" uuid="08716b20-43cb-4799-9b0d-2b96d7214788" version="1.0"/><qdm codeSystemName="National Quality Forum" datatype="Timing Element" id="40280381-3d61-56a7-013e-6b81e70055b1" name="Measurement Period" oid="2.16.840.1.113883.3.67.1.101.1.53" suppDataElement="false" taxonomy="NQF" uuid="40280381-3d61-56a7-013e-6b81e70055b1" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6b81e70255d7" name="Medical Reason" oid="2.16.840.1.113883.3.526.3.1007" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6b81e70255d7" version="1"/><qdm datatype="Diagnosis" id="31e6edfb-5cc1-40d4-9e3a-993dbaf7c4c0" name="Metastatic Sites Common to Colon Cancer" oid="2.16.840.1.113883.3.526.3.490" suppDataElement="false" taxonomy="Grouping" uuid="31e6edfb-5cc1-40d4-9e3a-993dbaf7c4c0" version="1.0"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Encounter, Performed" id="40280381-3d61-56a7-013e-6b81e70055b3" name="Office Visit" oid="2.16.840.1.113883.3.464.1003.101.12.1001" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6b81e70055b3" version="1"/><qdm codeSystemName="National Library of Medicine" datatype="Patient Characteristic Sex" id="40280381-3d61-56a7-013e-6b81e70055ac" name="ONC Administrative Sex" oid="2.16.840.1.113762.1.4.1" suppDataElement="true" taxonomy="AdministrativeGender" uuid="40280381-3d61-56a7-013e-6b81e70055ac" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Encounter, Performed" id="40280381-3d61-56a7-013e-6b81e70055b5" name="Patient Provider Interaction" oid="2.16.840.1.113883.3.526.3.1012" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6b81e70055b5" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6b81e70255d8" name="Patient Reason" oid="2.16.840.1.113883.3.526.3.1008" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6b81e70255d8" version="1"/><qdm codeSystemName="PHDSC" datatype="Patient Characteristic Payer" id="40280381-3d61-56a7-013e-6b81e70055af" name="Payer" oid="2.16.840.1.114222.4.11.3591" suppDataElement="true" taxonomy="SOP" uuid="40280381-3d61-56a7-013e-6b81e70055af" version="1"/><qdm codeSystemName="CDC NCHS" datatype="Patient Characteristic Race" id="40280381-3d61-56a7-013e-6b81e70055ad" name="Race" oid="2.16.840.1.114222.4.11.836" suppDataElement="true" taxonomy="CDCREC" uuid="40280381-3d61-56a7-013e-6b81e70055ad" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6b81e70255d9" name="System Reason" oid="2.16.840.1.113883.3.526.3.1009" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6b81e70255d9" version="1"/><qdm datatype="Procedure, Performed" id="281ca9b3-d41e-4000-827b-ca94481461ad" name="Pathology Evaluation" oid="2.16.840.1.113883.3.526.3.1098" suppDataElement="false" taxonomy="Grouping" uuid="281ca9b3-d41e-4000-827b-ca94481461ad" version="1.0"/></elementLookUp></measure>